Table 1.
Patent expiry of blockbuster drug in 2016
[Source: IMS (2012)]
| Drug (trade name) | Date of expiration/country | Company | Application area |
|---|---|---|---|
| Alimta® | 2016/US | Eli Lilly | Cancer |
| Benicar® | 2016/US | Daiichi Sankyo | Blood pressure medication |
| Benicar HTC® | 2016/US | Daiichi Sankyo | Blood pressure medication |
| Crestor® | 2016/US | Astra Zeneca | Lowering LDL cholesterol |
| Cubicin® | 2016/US | Merck | Bacterial infection |
| Zetia® | 2016/US | Merck | Lowering LDL cholesterol |
| Baraclude® | 2016/JP | Bristol–Myers Squibb | Antiviral medication (hepatitis B virus) |
| Glivec® | 2016/EU | Novartis | Myeloid leukemia |
| Vfend® | 2016/EU | Pfizer | Antifungal medication |
Patent expirations dates are subject to change due to patent litigation, additional patents and other market exclusivities. Patent expirations do not imply immediate generic availability